PL368816A1 - 3-podstawione pochodne 4-pirymidonu - Google Patents

3-podstawione pochodne 4-pirymidonu

Info

Publication number: PL368816A1
Authority: PL; Poland
Prior art keywords: substituted; pyrimidone derivatives; pyrimidone; derivatives
Prior art date: 2001-09-21

Application number

PL02368816A

Other languages

English (en)

Inventor

Fumiaki Uehara

Keiichi Aritomo

Aya Shoda

Shinsuke Hiki

Masahiro Okuyama

Yoshihiro Usui

Mitsuru Ooizumi

Kazutoshi Watanabe

Original Assignee

Mitsubishi Pharma Corporation

Sanofi-Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-21

Filing date

2002-09-20

Publication date

2005-04-04

2002-09-20 Application filed by Mitsubishi Pharma Corporation, Sanofi-Synthelabo filed Critical Mitsubishi Pharma Corporation

2005-04-04 Publication of PL368816A1 publication Critical patent/PL368816A1/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Oncology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PL02368816A 2001-09-21 2002-09-20 3-podstawione pochodne 4-pirymidonu PL368816A1 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2001331676		2001-09-21
JP2001331674		2001-09-21
JP2001331678		2001-09-21
JP2001331675		2001-09-21

Publications (1)

Publication Number	Publication Date
PL368816A1 true PL368816A1 (pl)	2005-04-04

Family

ID=27482650

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02368816A PL368816A1 (pl)	2001-09-21	2002-09-20	3-podstawione pochodne 4-pirymidonu

Country Status (23)

Country	Link
US (1)	US7572793B2 (pl)
EP (1)	EP1427709B1 (pl)
JP (1)	JP4368682B2 (pl)
KR (1)	KR100754596B1 (pl)
CN (1)	CN1319950C (pl)
AR (2)	AR043700A1 (pl)
AT (1)	ATE312827T1 (pl)
AU (1)	AU2002337498B2 (pl)
BR (1)	BR0212893A (pl)
CA (1)	CA2460177C (pl)
CY (1)	CY1105554T1 (pl)
DE (1)	DE60208051T2 (pl)
DK (1)	DK1427709T3 (pl)
EA (1)	EA007224B1 (pl)
ES (1)	ES2256540T3 (pl)
HU (1)	HUP0401898A3 (pl)
IL (2)	IL160701A0 (pl)
MX (1)	MXPA04002661A (pl)
NO (1)	NO326694B1 (pl)
NZ (1)	NZ531637A (pl)
PL (1)	PL368816A1 (pl)
TW (1)	TWI303171B (pl)
WO (1)	WO2003027080A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI241298B (en)	1998-09-25	2005-10-11	Mitsubishi Chem Corp	Pyrimidone derivatives
CA2460121C (en)	2001-09-21	2010-11-02	Mitsubishi Pharma Corporation	3-substituted-4-pyrimidone derivatives
CA2510170C (en) *	2002-12-16	2011-05-24	Mitsubishi Pharma Corporation	3-substituted-4-pyrimidone derivatives
US20040242566A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
TWI357408B (en) *	2003-03-26	2012-02-01	Mitsubishi Tanabe Pharma Corp	3-substituted-4-pyrimidone derivatives
CA2535619A1 (en)	2003-08-13	2005-02-24	Takeda Pharmaceutical Company Limited	4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
JP2007505121A (ja)	2003-09-08	2007-03-08	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
GB0325956D0 (en)	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
GEP20094679B (en)	2004-03-15	2009-05-10	Takeda Pharmaceuticals Co	Dipeptidyl peptidase inhibitors
AR050865A1 (es) *	2004-09-09	2006-11-29	Sanofi Aventis	Derivados de 2- morfolino-4-pirimidona
EP2266969A3 (en)	2004-09-29	2011-02-16	Mitsubishi Tanabe Pharma Corporation	6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors
US7872124B2 (en)	2004-12-21	2011-01-18	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
GB0510141D0 (en) *	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B3
GB0510142D0 (en) *	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds A1
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
ME02005B (me)	2005-09-14	2012-08-31	Takeda Pharmaceuticals Co	Inhibitori dipeptidil peptidaze za lečenje dijabetesa
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
TW200813015A (en) *	2006-03-15	2008-03-16	Mitsubishi Pharma Corp	2-(cyclic amino)-pyrimidone derivatives
AU2007287319A1 (en) *	2006-08-23	2008-02-28	Pfizer Products Inc.	Pyrimidone compounds as GSK-3 inhibitors
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR064660A1 (es) *	2006-12-26	2009-04-15	Mitsubishi Tanabe Pharma Corp	Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
TW200927134A (en) *	2007-09-14	2009-07-01	Mitsubishi Tanabe Pharma Corp	6-pyrimidinyl-pyrimid-2-one derivative
AU2008297814A1 (en) *	2007-09-14	2009-03-19	Sanofi-Aventis	3-Methyl-2- ( (2S) -2- (4- (3-Methyl-1, 2, 4-Oxadiazol-5-YL) phenyl) morpholino) -6- (pyrimidin-4-yl) Pyrimidin-4 (3H) -one as tau protein kinase inhibitor
EP2078717A1 (en)	2008-01-11	2009-07-15	sanofi-aventis	6-Pyrimidinyl-pyrimid-2-one derivative
AR076014A1 (es)	2009-04-02	2011-05-11	Sanofi Aventis	Derivados de 3- (1,4) oxazepan -4-pirimidona
US9006232B2 (en)	2009-08-13	2015-04-14	Mitsubishi Tanabe Pharma Corporation	Pyrimidone derivatives
WO2011019089A1 (en)	2009-08-13	2011-02-17	Mitsubishi Tanabe Pharma Corporation	Pyrimidone derivatives used as tau protein kinase 1 inhibitors
JP2013529181A (ja)	2010-03-25	2013-07-18	ザジェイ．デヴィッドグラッドストーンインスティテューツ	神経障害を治療するための組成物および方法
EP3345545B1 (en)	2011-04-21	2021-10-20	The Regents of The University of California	Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
RU2621050C2 (ru) *	2012-01-12	2017-05-31	Ф. Хоффманн-Ля Рош Аг	Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars)
ES2775192T3 (es)	2012-08-16	2020-07-24	Ipierian Inc	Procedimientos de tratamiento de una tauopatía
CA3124553A1 (en)	2012-10-25	2014-05-01	Bioverativ Usa Inc.	Anti-complement c1s antibodies and uses thereof
CN116063483A (zh)	2012-11-02	2023-05-05	美国比奥维拉迪维股份有限公司	抗补体C1s抗体和其用途
HUE050485T2 (hu)	2013-06-10	2020-12-28	Ipierian Inc	Tauopathia kezelési módszerei

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US187004A (en) *		1877-02-06		Improvement in water-wheels
JPS559099B2 (pl)	1972-08-07	1980-03-07
JPS4935633A (pl)	1972-08-09	1974-04-02
JPS5124008B2 (pl)	1972-08-10	1976-07-21
JPS4935632A (pl)	1972-08-10	1974-04-02
JPS5271481A (en)	1975-12-10	1977-06-14	Yoshitomi Pharmaceut Ind Ltd	Synthesis of pyridylpyrimidines
JPS52139085A (en)	1976-05-13	1977-11-19	Hokuriku Pharmaceutical	22allylpiperazine derivative and method for its preparation
US4507302A (en) *	1979-03-19	1985-03-26	The Upjohn Company	Method for treating arthritis with 6-aryl pyrimidine compounds
US4619933A (en) *	1979-09-28	1986-10-28	The Upjohn Company	6-aryl pyrimidines for treating aplastic anemia
US4725600A (en)	1984-07-13	1988-02-16	Fujisawa Pharmaceutical Co., Ltd.	Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
GB8906946D0 (en) *	1988-04-22	1989-05-10	Ici Plc	Novel compounds
DE58908208D1 (de)	1988-07-29	1994-09-22	Ciba Geigy Ag	Thiouracile als Stabilisatoren für chlorhaltige Polymerisate.
ATE398176T1 (de)	1991-12-06	2008-07-15	Max Planck Gesellschaft	Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit
DE4206145A1 (de) *	1992-02-28	1993-09-02	Basf Ag	Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide
JP3324611B2 (ja)	1992-07-03	2002-09-17	三菱化学株式会社	タウ蛋白質のリン酸化方法
JPH06329551A (ja)	1993-03-22	1994-11-29	Mitsubishi Kasei Corp	アルツハイマー病の予防または治療薬およびそのスクリーニング方法
EP0723533A1 (en) *	1993-10-12	1996-07-31	The Du Pont Merck Pharmaceutical Company	1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US6410729B1 (en)	1996-12-05	2002-06-25	Amgen Inc.	Substituted pyrimidine compounds and methods of use
WO1998024782A2 (en)	1996-12-05	1998-06-11	Amgen Inc.	Substituted pyrimidine compounds and their use
US6096753A (en)	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
HUP0001140A3 (en)	1996-12-05	2002-05-28	Amgen Inc Thousand Oaks	Substituted pyrimidinone and pyridone compounds and methods of use
AR048564A1 (es)	1996-12-05	2006-05-10	Amgen Inc	Compuestos de pirimidina sustituidos,composicion farmaceutica y usos para la fabricacion de medicamentos particularmente para el tratamiento de enfermedades mediadas por tnf-alfa, il-1 beta, il-6 y/o il-8
WO1998042699A1 (en) *	1997-03-26	1998-10-01	Taisho Pharmaceutical Co., Ltd.	4-tetrahydropyridylpyrimidine derivatives
TWI241298B (en) *	1998-09-25	2005-10-11	Mitsubishi Chem Corp	Pyrimidone derivatives
DE60110391T2 (de) *	2000-02-25	2006-01-26	F. Hoffmann-La Roche Ag	Adenosin-rezeptor modulatoren
AU2001262150A1 (en)	2000-03-23	2001-10-03	Mitsubishi Pharma Corporation	2-(nitrogen-heterocyclic)pyrimidone derivatives
EP1136482A1 (en)	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
CA2460121C (en)	2001-09-21	2010-11-02	Mitsubishi Pharma Corporation	3-substituted-4-pyrimidone derivatives
CA2510170C (en)	2002-12-16	2011-05-24	Mitsubishi Pharma Corporation	3-substituted-4-pyrimidone derivatives
TWI357408B (en)	2003-03-26	2012-02-01	Mitsubishi Tanabe Pharma Corp	3-substituted-4-pyrimidone derivatives

2002
- 2002-09-20 MX MXPA04002661A patent/MXPA04002661A/es active IP Right Grant
- 2002-09-20 AR ARP020103546A patent/AR043700A1/es unknown
- 2002-09-20 EP EP02772870A patent/EP1427709B1/en not_active Expired - Lifetime
- 2002-09-20 TW TW091121652A patent/TWI303171B/zh active
- 2002-09-20 NZ NZ531637A patent/NZ531637A/en not_active IP Right Cessation
- 2002-09-20 ES ES02772870T patent/ES2256540T3/es not_active Expired - Lifetime
- 2002-09-20 AR ARP020103547A patent/AR036604A1/es active IP Right Grant
- 2002-09-20 CN CNB028180178A patent/CN1319950C/zh not_active Expired - Fee Related
- 2002-09-20 US US10/489,607 patent/US7572793B2/en not_active Expired - Fee Related
- 2002-09-20 CA CA2460177A patent/CA2460177C/en not_active Expired - Fee Related
- 2002-09-20 WO PCT/JP2002/009684 patent/WO2003027080A1/en not_active Ceased
- 2002-09-20 AU AU2002337498A patent/AU2002337498B2/en not_active Ceased
- 2002-09-20 BR BR0212893-4A patent/BR0212893A/pt not_active Application Discontinuation
- 2002-09-20 HU HU0401898A patent/HUP0401898A3/hu unknown
- 2002-09-20 AT AT02772870T patent/ATE312827T1/de active
- 2002-09-20 JP JP2003530670A patent/JP4368682B2/ja not_active Expired - Lifetime
- 2002-09-20 DE DE60208051T patent/DE60208051T2/de not_active Expired - Lifetime
- 2002-09-20 EA EA200400452A patent/EA007224B1/ru not_active IP Right Cessation
- 2002-09-20 PL PL02368816A patent/PL368816A1/pl not_active Application Discontinuation
- 2002-09-20 KR KR1020047004113A patent/KR100754596B1/ko not_active Expired - Fee Related
- 2002-09-20 IL IL16070102A patent/IL160701A0/xx unknown
- 2002-09-20 DK DK02772870T patent/DK1427709T3/da active
2004
- 2004-03-03 IL IL160701A patent/IL160701A/en not_active IP Right Cessation
- 2004-04-20 NO NO20041604A patent/NO326694B1/no not_active IP Right Cessation
2006
- 2006-03-09 CY CY20061100327T patent/CY1105554T1/el unknown

Also Published As

Publication number	Publication date
EP1427709B1 (en)	2005-12-14
ES2256540T3 (es)	2006-07-16
JP2005510472A (ja)	2005-04-21
MXPA04002661A (es)	2004-11-22
IL160701A (en)	2009-06-15
KR100754596B1 (ko)	2007-09-05
HUP0401898A2 (hu)	2004-12-28
HK1068608A1 (en)	2005-04-29
BR0212893A (pt)	2004-08-03
JP4368682B2 (ja)	2009-11-18
DE60208051T2 (de)	2006-06-22
EP1427709A1 (en)	2004-06-16
AR043700A1 (es)	2005-08-10
WO2003027080A1 (en)	2003-04-03
DE60208051D1 (de)	2006-01-19
EA007224B1 (ru)	2006-08-25
CY1105554T1 (el)	2010-07-28
NO20041604L (no)	2004-06-17
HUP0401898A3 (en)	2005-08-29
AR036604A1 (es)	2004-09-22
ATE312827T1 (de)	2005-12-15
CN1319950C (zh)	2007-06-06
KR20040054690A (ko)	2004-06-25
CA2460177C (en)	2010-03-23
CA2460177A1 (en)	2003-04-03
US7572793B2 (en)	2009-08-11
AU2002337498B2 (en)	2006-08-10
NZ531637A (en)	2005-12-23
TWI303171B (en)	2008-11-21
IL160701A0 (en)	2004-08-31
DK1427709T3 (da)	2006-04-03
US20050130967A1 (en)	2005-06-16
NO326694B1 (no)	2009-02-02
EA200400452A1 (ru)	2004-08-26
CN1555367A (zh)	2004-12-15

Publication	Publication Date	Title
ZA200309522B (en)	2005-02-23	Substituted cyclohexane-1-4diamine derivatives
IL160701A0 (en)	2004-08-31	3-substituted-4-pyrimidone derivatives
DE60209787D1 (en)	2006-05-04	Flächiges implantat
DE50201180D1 (en)	2004-11-04	Organopolysiloxan/polyharnstoff/polyurethan-blockcopolymere
IL158388A0 (en)	2004-05-12	Novel arylheteroalkylamine derivatives
HUP0303449A3 (en)	2005-02-28	Substituted benzofuran-2-carboxamides derivatives
EP1353546A4 (en)	2009-07-22	METHOD AND DEVICE FOR MONITORING PULSATION FOR TREATMENT DEVICE
HUP0401949A3 (en)	2009-07-28	4-imidazolin-2-one derivatives
HUP0303186A3 (en)	2007-06-28	4-aminobenzopyran derivatives
HUP0500026A3 (en)	2008-02-28	N-heteroarylnicotinamide derivatives
IL159064A0 (en)	2004-05-12	New phenylalkyloxy- phenyl derivatives
EP1364954A4 (en)	2009-10-28	Dicarba closo DODECARBORANDERIVATE
DE50203686D1 (en)	2005-08-25	Substituierte c-furan-2-yl-methylamin- und c-thiophen-2-yl-methylamin-derivate
DE50214962D1 (en)	2011-04-28	Heterocyclylarylsulfonamide
DE60236364D1 (en)	2010-06-24	Hepatitis-c-virus-impfstoff
AU2002313943A8 (en)	2008-01-03	Electromobile
GB0112539D0 (en)	2001-07-11	Sleepover
SI1427709T1 (sl)	2006-04-30	3-substituirani-4-pirimidonski derivati
CA91502S (en)	2001-01-31	Bedboard
CA92665S (en)	2001-06-22	Bedboard
CA93646S (en)	2001-10-26	Fauteuil
GB0104759D0 (en)	2001-04-18	Floodlock
GB0109895D0 (en)	2001-06-13	Portadam
GB0107951D0 (en)	2001-05-23	Paulinea
GB0106702D0 (en)	2001-05-09	Reactor-vision

Legal Events

Date	Code	Title	Description
2013-11-29	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)